XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurement
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurement
3.
Fair Value Measurement

The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation:

 

 

 

September 30, 2021

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

 

(in thousands)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

69,644

 

 

$

69,644

 

 

$

 

 

$

 

Short-term marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury notes

 

 

60,555

 

 

 

 

 

 

60,555

 

 

 

 

Commercial paper

 

 

184,277

 

 

 

 

 

 

184,277

 

 

 

 

Corporate debt securities

 

 

134,351

 

 

 

 

 

 

134,351

 

 

 

 

Supranational debt securities

 

 

40,081

 

 

 

 

 

 

40,081

 

 

 

 

Total short-term marketable securities

 

 

419,264

 

 

 

 

 

 

419,264

 

 

 

 

Investment in equity securities

 

 

17,707

 

 

 

17,707

 

 

 

 

 

 

 

LianBio Warrants

 

 

2,878

 

 

 

 

 

 

 

 

 

2,878

 

Total financial assets

 

$

509,493

 

 

$

87,351

 

 

$

419,264

 

 

$

2,878

 

Liability

 

 

 

 

 

 

 

 

 

 

 

 

Embedded derivative

 

$

1,413

 

 

$

 

 

$

 

 

$

1,413

 

 

 

 

December 31, 2020

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

 

(in thousands)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

266,437

 

 

$

266,437

 

 

$

 

 

$

 

Short-term marketable securities:

 

 

 

 

 

 

 

 

 

 

 

 

U.S. treasury bills

 

 

14,999

 

 

 

 

 

 

14,999

 

 

 

 

U.S. treasury notes

 

 

45,391

 

 

 

 

 

 

45,391

 

 

 

 

Commercial paper

 

 

144,851

 

 

 

 

 

 

144,851

 

 

 

 

Corporate debt securities

 

 

45,770

 

 

 

 

 

 

45,770

 

 

 

 

Total short-term marketable securities

 

 

251,011

 

 

 

 

 

 

251,011

 

 

 

 

LianBio Warrants

 

 

3,338

 

 

 

 

 

 

 

 

 

3,338

 

Total financial assets

 

$

520,786

 

 

$

266,437

 

 

$

251,011

 

 

$

3,338

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

LEO call option liability

 

$

5,550

 

 

$

 

 

$

 

 

 

5,550

 

Embedded derivative

 

 

1,340

 

 

 

 

 

 

 

 

 

1,340

 

Total financial liabilities

 

$

6,890

 

 

$

 

 

$

 

 

$

6,890

 

 

There were no transfers between Level 1, Level 2 or Level 3 during the periods presented.

There are uncertainties on the fair value measurement of the instruments classified under Level 3 due to the use of unobservable inputs and interrelationships between these unobservable inputs, which could result in higher or lower fair value measurements.

Marketable Securities

The fair value of our marketable securities classified within Level 2 is based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications.

Investment in Equity Securities

We classify our investment in equity securities, which are currently equity securities of publicly held companies, within Level 1 as the fair values of these equity securities are derived from observable inputs such as quoted prices in active markets.

LEO Call Option Liability

The valuation of the LEO call option contained unobservable inputs that reflected our own assumptions for which there was little, if any, market activity at the measurement date. Accordingly, the LEO call option liability was remeasured to fair value on a recurring basis using unobservable inputs that were classified as Level 3 inputs. The uncertainty of the fair value measurement due to the use of unobservable inputs and interrelationships between these unobservable inputs could have resulted in higher or lower fair value measurement.

On March 30, 2021, LEO provided a notice of termination of the LEO call option effective April 15, 2021. As a result and based on the facts and circumstances that existed as of March 31, 2021, we evaluated that the likelihood of LEO exercising said option was remote and we remeasured the LEO call option liability to zero as of March 31, 2021. The following table sets forth a summary of the change in the estimated fair value of the LEO call option recorded in “Other income (expense), net”:

 

 

 

Total

 

 

 

(in thousands)

 

Balance as of December 31, 2020

 

$

5,550

 

Change in fair value upon notice of termination
  of the LEO call option

 

 

(5,550

)

Balance as of March 31, 2021

 

$

 

Historically, we estimated the fair value of the LEO call option by estimating the fair value of various clinical, regulatory, and sales milestones based on the estimated risk and probability of achievement of each milestone, and allocated the value using a Black-Scholes option pricing model with the following assumptions as of December 31, 2020:

 

 

 

December 31,

 

 

2020

Probability of milestone achievement

 

12.0%-84.0%

Discount rate

 

0.1%-14.3%

Expected term (in years)

 

1.25-6.25

Expected volatility

 

80.0%-95.0%

Risk-free interest rate

 

1.16%-1.53%

Dividend yield

 

 —

 

Eidos Embedded Derivative Liability in Loan Agreement

For the SVB and Hercules Loan entered into in November 2019 and prepaid in April 2021 (see Note 9), Eidos determined that the requirement to pay a fee upon certain events (“Success Fee”) is an embedded derivative liability to be measured at fair value. The fair value of the derivative was determined based on an income approach that identified the cash flows using a “with-and-without” valuation methodology. The inputs used to determine the estimated fair value of the derivative instrument were based primarily on the probability of an underlying event triggering the embedded derivative occurring and the timing of such event. The Success Fee survives the prepayment of the SVB and Hercules Loan per the terms of the contract; and, therefore, we continue to carry the embedded derivative liability at its fair value until it is settled or it expires.

Notes

The fair values of our 2.25% convertible senior notes due 2029 (the “2029 Notes”) and our 2.50% convertible senior notes due 2027 (the “2027 Notes”) (collectively, the “Notes”, see Note 9), which differ from their respective carrying values, are determined by prices for the Notes observed in market trading. The market for trading of the Notes is not considered to be an active market and therefore the estimate of fair value is based on Level 2 inputs. As of September 30, 2021, the estimated fair value of our 2029 Notes and 2027 Notes, which have aggregate face values of $747.5 million and $550.0 million, respectively, were $647.7 million and $759.8 million, respectively, based on their market prices on the last trading day for the period. As of December 31, 2020, the estimated fair value of the 2027 Notes was $997.9 million based on the market price on the last trading day for the period.

Term Loans

The fair value of our outstanding term loans (see Note 9) is estimated using the net present value of the payments, discounted at an interest rate that is consistent with a market interest rate, which is a Level 2 input. The estimated fair value of our outstanding term loans approximates the carrying amount, as the term loans bear a floating rate that approximates the market interest rate.